Updates since publication
Regulatory changes that affect the book or these materials are logged here, newest first. The book’s Chapters 1 and 14 point to this page.
Regulatory status · as of 27 September 2026
| Area |
Status |
Primary source |
| US |
The DSUR is accepted in place of the IND annual report. FDA’s proposed rule to require it (87 FR 75551, 9 December 2022; RIN 0910-AI37) is not final; the Unified Agenda projects a final rule for July 2027. |
Federal Register |
| EU |
Annual safety report under Article 43 of Regulation (EU) No 536/2014, submitted through CTIS. Clinical Trials Regulation Q&A version 7.2, 27 March 2026. |
EudraLex Vol. 10 Q&A |
| UK |
Amended clinical trials regulations (SI 2025/538) in force since 28 April 2026: annual DSUR to MHRA within 60 days. |
MHRA guidance |
| China |
CDE DSUR Q&A (Notice 2026 No. 19) in effect since 24 February 2026: submission within 60 calendar days of the DLP. |
CDE notice |
| Japan |
Periodic report rules per MHLW notification 0831-14 (31 August 2020), amended 26 December 2023. |
MHLW notification |
| ICH |
E2F Step 4 (17 August 2010) remains current. |
ICH E2F |
| CIOMS |
Working Group XVI on the DSUR under way since February 2025; no report yet. |
CIOMS WG XVI |
Change log
| Date |
Change |
Affects |
| 27 September 2026 |
Baseline status recorded. |
— |